Apr 24, 2025 / 12:00PM GMT
Operator
Good day and welcome to the Hansa Biopharma Interim results and Q1 earnings conference call.
I would now like to turn the conference over to Peter Nicklin, Chairman of the board, Hansa Pharma, please. Go ahead.
Peter Nicklin - Hansa Biopharma AB - Independent Chairman of the Board
Good afternoon and good morning everybody.
Welcome to the Hansa BioPharma conference call to review our Q1 results for 2025.
I'm Peter Nicklin, Chairman of the board of Hansa BioPharma. You'll recollect in June this year, I actually reached my 3rd year anniversary as Chairman of the board.
Joining me today is Evan Ballantyne, Chief Financial Officer, Hito Kaufmann, our chief R&D officer. And Renée Aguiar-Lucander, our newly appointed CEO.
Before we turn to the Q1 results, you are most likely aware that earlier today we announced the departure of Siron Tolsto, CEO of Hansa BioPharma, effective immediately. Over the course of his tenure, whilst with the organization, CERN successfully navigated the company through several key
Q1 2025 Hansa Biopharma AB Earnings Call Transcript
Apr 24, 2025
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers